NEW YORK ( TheStreet) -- CHANGE IN RATINGS Ariad Pharmaceutical ( ARIA) was initiated with a Buy rating at UBS. $20 price target. Near-term driver of phase I/II date from AP26113, UBS said. Bed Bath & Beyond ( BBBY) was downgraded at Canaccord Genuity from Buy to Hold. $73 price target. Company is losing market share, Canaccord said. Bill Barrett ( BBG) was initiated with a Hold rating at Deutsche Bank. $30 price target. Company remains highly leveraged to natural gas, Deutsche said. BioMarin ( BMRN) was initiated with a Buy rating at UBS. $43 price target. GALNS can be a $500 million product, UBS said. Electronic Arts ( EA) was initiated with a Neutral rating at Ascendiant. $16 price target. Concerns remain around industry growth and the company's key games, Ascendiant said. Human Genome ( HGSI) was initiated with a Neutral rating at UBS. $8 price target. Company will continue to trade on monthly IMS sales for Benlysta, UBS said. IDT Corp. ( IDT) was upgraded to hold at TheStreet Ratings. MAP Pharmaceuticals ( MAPP) was downgraded to sell at TheStreet Ratings. MercadoLibre ( MELI) was initiated with a Neutral rating at Goldman Sachs. Valuation call, based on a $93 price target, Goldman said. Mattress Firm ( MFRM) was initiated with a Hold rating at Stifel Nicolaus. Valuation call, as the stock is up 132% since its IPO. Packaging Corp. ( PKG) was upgraded at JP Morgan from Underweight to Neutral. Company continues to execute well. AT&T ( T) was upgraded at JP Morgan to Overweight from Neutral. $33 price target. Higher tablet demand should drive ARPU growth, JP Morgan said. United Therapeutics ( UTHR) was downgraded at Leerink Swann to Market Perform. Company is facing increased generic risk, Leerink Swann said. Whiting Petroleum ( WLL) was initiated with a Buy rating at Brean Murray. $70 price target. Company was also placed on the Focus List. Company should deliver more consistent drilling results, Brean Murray said.